Scilex Holding (SCLX) Depreciation and Depletion (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Depreciation and Depletion of $800000.0 for Q1 2026, up 79900.0% year-over-year from N/an in Q1 2025, and up 215.08% on a QoQ basis from $253900.0 in Q4 2025.
Scilex Holding (SCLX) Depreciation and Depletion (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Depreciation and Depletion for 5 consecutive years, with $800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 79900.0% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 9517.27% YoY), while the FY2025 annual figure was $258900.0, up 1749.29% from the prior year.
- Depreciation and Depletion came in at $800000.0 for Q1 2026 at Scilex Holding, up from $253900.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $800000.0 in Q1 2026, with the low at $1000.0 in Q1 2025.
- Average Depreciation and Depletion over 5 years is $68405.9, with a median of $10000.0 recorded in 2022.
- Across the five-year window, Depreciation and Depletion slumped 75.0% in 2024 and jumped 79900.0% in 2026, its largest moves.
- Year by year, Depreciation and Depletion stood at $10000.0 in 2022, then retreated by 20.0% to $8000.0 in 2023, then plunged by 75.0% to $2000.0 in 2024, then surged by 12595.0% to $253900.0 in 2025, then jumped by 215.08% to $800000.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $800000.0, $253900.0, and $2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 253,900.00 |
| Dec 31, 2025 | 253,900.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |